Journal of Antimicrobial Chemotherapy, Vol 39, 241-246, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy
N Galanakis, H Giamarellou, T Moussas and E Dounis
We evaluated ciprofloxacin, ofloxacin and pefloxacin regimens for the
treatment of chronic osteomyelitis due to Gram-negative multiresistant
organisms. The study was open, nonrandomized and included 28, 21 and 16
patients, respectively. The 4-fluoroquinolone regimens were 1000 mg, 400 mg
and 400-800 mg bd, for a mean duration of 137, 163 and 134 days,
respectively. Pseudomonas aeruginosa was the most common pathogen, isolated
in 33 individuals. Patients were followed clinically, bacteriologically and
radiologically during treatment and for 2-5 years after discontinuation of
therapy. Clinical outcome at the end of therapy was successful in 79%, 81%
and 75%, improvement occurred in 11%, 10% and 19%, and the failure rate was
11%, 10% and 6%, while 11%, 5% and 6% relapsed, respectively. At the end of
follow-up the bacterial eradication rate was 68%, 76% and 69%,
respectively. Fluoroquinolone resistance emerged in 18%, 19% and 13% of
ciprofloxacin, ofloxacin and pefloxacin recipients, respectively. The newer
quinolones were safe and well tolerated and should be considered as the
contemporary treatment of choice for chronic Gram-negative osteomyelitis,
particularly whenever P. aeruginosa is implicated.
JOURNAL ARTICLE
Chronic osteomyelitis caused by multi-resistant Gram-negative bacteria: evaluation of treatment with newer quinolones after prolonged follow-up
First Department of Propedeutic Medicine, Athens University Medical School, Greece.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Kanellakopoulou, G. C. Thivaios, M. Kolia, I. Dontas, L. Nakopoulou, E. Dounis, E. J. Giamarellos-Bourboulis, A. Andreopoulos, P. Karagiannakos, and H. Giamarellou Local Treatment of Experimental Pseudomonas aeruginosa Osteomyelitis with a Biodegradable Dilactide Polymer Releasing Ciprofloxacin Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2335 - 2339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Makinen, M. Veiranto, P. Lankinen, N. Moritz, J. Jalava, P. Tormala, and H. T. Aro In vitro and in vivo release of ciprofloxacin from osteoconductive bone defect filler J. Antimicrob. Chemother., December 1, 2005; 56(6): 1063 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. R. Darley and A. P. MacGowan Antibiotic treatment of Gram-positive bone and joint infections J. Antimicrob. Chemother., June 1, 2004; 53(6): 928 - 935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Perez-Vazquez, F. Roman, B. Aracil, R. Canton, and J. Campos Laboratory Detection of Haemophilus influenzae with Decreased Susceptibility to Nalidixic Acid, Ciprofloxacin, Levofloxacin, and Moxifloxacin Due to gyrA and parC Mutations J. Clin. Microbiol., March 1, 2004; 42(3): 1185 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. CALZA, R. MANFREDI, G. MARINACCI, L. FORTUNATO, and F. CHIODO Community-acquired Pseudomonas aeruginosa sacro-iliitis in a previously healthy patient J. Med. Microbiol., July 1, 2002; 51(7): 620 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kanellakopoulou, M. Kolia, A. Anastassiadis, T. Korakis, E. J. Giamarellos-Bourboulis, A. Andreopoulos, E. Dounis, and H. Giamarellou Lactic Acid Polymers as Biodegradable Carriers of Fluoroquinolones: An In Vitro Study Antimicrob. Agents Chemother., March 1, 1999; 43(3): 714 - 716. [Abstract] [Full Text]
|
|